company background image
ALPI

Pixium Vision ENXTPA:ALPIX Stock Report

Last Price

€0.51

Market Cap

€29.9m

7D

1.0%

1Y

-49.0%

Updated

27 May, 2022

Data

Company Financials +
ALPIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALPIX Stock Overview

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application.

Pixium Vision Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Pixium Vision
Historical stock prices
Current Share Price€0.51
52 Week High€1.33
52 Week Low€0.48
Beta1.17
1 Month Change3.61%
3 Month Change-22.31%
1 Year Change-49.04%
3 Year Change-65.97%
5 Year Change-92.20%
Change since IPO-93.72%

Recent News & Updates

Shareholder Returns

ALPIXFR Medical EquipmentFR Market
7D1.0%4.4%-1.1%
1Y-49.0%-5.8%-5.9%

Return vs Industry: ALPIX underperformed the French Medical Equipment industry which returned -5.8% over the past year.

Return vs Market: ALPIX underperformed the French Market which returned -5.9% over the past year.

Price Volatility

Is ALPIX's price volatile compared to industry and market?
ALPIX volatility
ALPIX Average Weekly Movement5.2%
Medical Equipment Industry Average Movement7.0%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: ALPIX is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ALPIX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201140Lloyd Diamondhttps://www.pixium-vision.com

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC.

Pixium Vision Fundamentals Summary

How do Pixium Vision's earnings and revenue compare to its market cap?
ALPIX fundamental statistics
Market Cap€29.87m
Earnings (TTM)-€10.93m
Revenue (TTM)€1.79m

16.5x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALPIX income statement (TTM)
Revenue€1.79m
Cost of Revenue€0
Gross Profit€1.79m
Other Expenses€12.72m
Earnings-€10.93m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin100.00%
Net Profit Margin-610.27%
Debt/Equity Ratio139.1%

How did ALPIX perform over the long term?

See historical performance and comparison

Valuation

Is Pixium Vision undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


5.09x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALPIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALPIX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALPIX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.

PE vs Market: ALPIX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALPIX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALPIX is overvalued based on its Price-To-Book Ratio (5.1x) compared to the FR Medical Equipment industry average (2.2x).


Future Growth

How is Pixium Vision forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALPIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALPIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALPIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALPIX's revenue is expected to decline over the next 3 years (-35.5% per year).

High Growth Revenue: ALPIX's revenue is forecast to decline over the next 3 years (-35.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALPIX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Pixium Vision performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


5.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALPIX is currently unprofitable.

Growing Profit Margin: ALPIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALPIX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.

Accelerating Growth: Unable to compare ALPIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALPIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).


Return on Equity

High ROE: ALPIX has a negative Return on Equity (-187.99%), as it is currently unprofitable.


Financial Health

How is Pixium Vision's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALPIX's short term assets (€16.9M) exceed its short term liabilities (€6.5M).

Long Term Liabilities: ALPIX's short term assets (€16.9M) exceed its long term liabilities (€7.3M).


Debt to Equity History and Analysis

Debt Level: ALPIX has more cash than its total debt.

Reducing Debt: ALPIX's debt to equity ratio has increased from 6.1% to 139.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALPIX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALPIX has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 12.1% each year.


Dividend

What is Pixium Vision current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALPIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALPIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALPIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALPIX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALPIX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Lloyd Diamond (53 yo)

3yrs

Tenure

€401,017

Compensation

Mr. Lloyd Diamond is the Chief Executive Officer at Pixium Vision SA since May 13, 2019 and serves as its Director since May 29, 2019. He was the Chief Business Officer of BONESUPPORT AB since January 22,...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Lloyd's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Insufficient data to compare Lloyd's compensation with company performance.


Leadership Team

Experienced Management: ALPIX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: ALPIX's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.


Top Shareholders

Company Information

Pixium Vision SA's employee growth, exchange listings and data sources


Key Information

  • Name: Pixium Vision SA
  • Ticker: ALPIX
  • Exchange: ENXTPA
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €29.874m
  • Shares outstanding: 58.58m
  • Website: https://www.pixium-vision.com

Number of Employees


Location

  • Pixium Vision SA
  • 74 rue du Faubourg Saint-Antoine
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/27 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.